Targeting HRAS Mutations With Investigational Tipifarnib May Hold Promise in Some Tumor TypesOctober 30th 2020
The high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.
New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment FocusApril 3rd 2020
PARP inhibitors following platinum-based chemotherapy as well as immunotherapy combinations have shown early signs of efficacy in metastatic pancreatic cancer with homologous recombination deficiency, according to data presented at the 2020 Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco, California.
Immunotherapies Combined With Lung Cancer Treatments Could Be Practice ChangingOctober 6th 2016
Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.
DIAPH3 Predicts Breast and Prostate Cancer Responses to ChemotherapiesAugust 18th 2015
A publication in Scientific Reports has identified a novel biomarker, diaphanous-related formin-3 (DIAPH3), which may help predict response to taxane-based chemotherapies in patients with metastatic breast or prostate cancer.
Preclinical Trial of High-Grade Serous Ovarian Cancer Shows Efficacy With Birinapant Plus CarboplatinAugust 11th 2015
Combination therapy with birinapant and carboplatin may be more effective than either therapy alone for treatment of high-grade serous ovarian cancers (HGSCs) with high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA125-negative cells.
New Genome Characterization Center to Focus on Proteomics Across Tumor TypesJuly 27th 2015
The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).
AR-V7 in Prostate Cancer Cells Introduces Potential Therapeutic Target for CRPCMarch 9th 2015
A recent study showed that the androgen receptor (AR) splice variant AR-V7 activated full-length AR through an alternative biosynthesis pathway and increased citrate utilization through altered metabolic activities, which may partially explain its resistance to conventional androgen deprivation therapy (ADT).